ArisGlobal Strengthens Partnership with Sitero
A significant advancement in drug development is underway as ArisGlobal, a prominent innovator in life sciences technology, enhances its collaboration with Sitero LLC, a provider of advanced clinical trial solutions. This strategic move aims to deliver top-tier capabilities across the entire drug development technology spectrum.
Enhancing Drug Development Efficiency
This partnership is set to improve connectivity and data flow throughout the drug development platform. By merging their technologies, ArisGlobal and Sitero are poised to boost interoperability across Clinical, Safety, Regulatory, Medical Affairs, and Quality platforms. This thorough integration demonstrates the companies' dedication to enhancing life sciences efficiency.
Advantages for Global Life Sciences Clients
The expanded partnership offers a unique solution specifically designed for global life sciences clients. By integrating Sitero's eClinical platform with ArisGlobal's LifeSphere R&D technology suite, the collaboration resolves issues related to duplicate data entry and reconciliation. This synergy aims to enhance data harmonization and operational efficiency, ultimately benefiting patient safety during clinical trials.
Key Benefits of the Collaboration
This innovative partnership brings several significant advantages:
- Interoperability: Automating secure data sharing leads to more efficient workflows, optimizing resource allocation and reducing costs.
- Data Integrity and Harmonization: Improved accuracy and reliability through elevated data quality at every trial stage.
- Compliance: Enhanced accuracy in submissions, supported by thorough source data verification.
- Intelligent Automation: Automation of data processes, including touchless archival capabilities, reduces clinical trial errors.
- Simplified IT Infrastructure: The integration streamlines customer operations under a single agreement across all R&D technology areas, minimizing overall operational complexities.
Insights from Industry Leaders
Aman Wasan, CEO of ArisGlobal, shared insights on the strategic investment in their initiatives, stating, "Our focus is on maximizing end-user benefits while ensuring excellent returns on investment for our partners worldwide." He further elaborated on LifeSphere's capabilities, powered by LifeSphere NavaX, an innovative cognitive computing engine that combines advanced Gen AI and LLM solutions for the future of life sciences.
Sitero's Commitment
Sankesh Abbhi, CEO of Sitero, echoed this sentiment, emphasizing their dedication to utilizing extensive business process expertise and advanced automation consulting to create an optimized clinical platform for pharmaceutical companies. The enhanced partnership strengthens the offering by connecting both Mentor and LifeSphere platforms.
Looking Ahead
This partnership marks a significant evolution in technology collaborations, building on previous implementations announced in the past. As ArisGlobal and Sitero work closely together, they are paving the way for future innovations that could profoundly impact drug development.
About ArisGlobal
ArisGlobal is a pioneering technology company in the life sciences sector, particularly recognized for its LifeSphere platform. By transforming traditional drug development methods, ArisGlobal empowers various organizations to innovate and navigate the journey from development to market efficiently. With a global presence that includes the United States, Europe, India, Japan, and China, ArisGlobal remains at the forefront of industry advancements.
About Sitero
Sitero is a next-generation clinical research partner, distinguished by its technology-driven services that enhance the safety and speed of drug development processes. Their approach combines innovative strategies with seasoned expertise, facilitating a swift pathway for clinical trial advancements. Sitero operates across the US, UK, Poland, Australia, and India, serving a diverse range of clients in the life sciences sector.
Frequently Asked Questions
What is the main goal of the ArisGlobal and Sitero partnership?
The partnership aims to enhance connectivity and data integration across the drug development process, improving efficiency and patient safety.
How does the integration of technologies benefit clinical trials?
The integration reduces redundancy by eliminating double data entry and streamlining data processes, leading to increased accuracy and efficiency.
What is LifeSphere?
LifeSphere is ArisGlobal's comprehensive R&D technology suite designed to optimize workflows in life sciences, offering seamless interoperability across different trial platforms.
Who are the key leaders involved in this partnership?
Aman Wasan is the CEO of ArisGlobal, while Sankesh Abbhi serves as the CEO of Sitero, both leading the strategic initiatives of their respective companies.
What are the global locations of ArisGlobal and Sitero?
ArisGlobal has a presence in the US, Europe, India, Japan, and China, while Sitero operates in the US, UK, Poland, Australia, and India.
